XSHE
000739
Market cap2.32bUSD
Jun 16, Last price
14.36CNY
1D
-1.17%
1Q
-6.21%
Jan 2017
90.70%
Name
Apeloa Pharmaceutical Co Ltd
Chart & Performance
Profile
Apeloa Pharmaceutical Co.,Ltd researches and develops, produces, and sells pharmaceutical products in China and internationally. It provides products in the cardio-cerebrovascular, anti-infection, anti-viral, anti-tumor, and other treatment areas. The company offers preparations, raw material intermediates, and veterinary drugs primarily under the Tianliwei, Beshin, Yosemade, Jutai, and other brands. It also provides contract research and development, and production services for pharmaceutical companies. The company is headquartered in Dongyang, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 12,021,863 4.77% | 11,474,162 8.81% | 10,544,905 17.92% | |||||||
Cost of revenue | 10,379,656 | 9,833,407 | 9,167,113 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 1,642,207 | 1,640,756 | 1,377,792 | |||||||
NOPBT Margin | 13.66% | 14.30% | 13.07% | |||||||
Operating Taxes | 172,444 | 149,337 | 22,894 | |||||||
Tax Rate | 10.50% | 9.10% | 1.66% | |||||||
NOPAT | 1,469,764 | 1,491,418 | 1,354,898 | |||||||
Net income | 1,031,122 -2.29% | 1,055,341 6.69% | 989,174 3.52% | |||||||
Dividends | (335,879) | |||||||||
Dividend yield | 1.33% | |||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 814,026 | 807,796 | 571,865 | |||||||
Long-term debt | 97,606 | 27,660 | 281,249 | |||||||
Deferred revenue | 31,686 | 30,620 | 15,120 | |||||||
Other long-term liabilities | 36,000 | 72,000 | 72,000 | |||||||
Net debt | (2,749,987) | (2,919,278) | (2,791,152) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 1,208,754 | 1,031,363 | 1,326,107 | |||||||
CAPEX | (630,467) | |||||||||
Cash from investing activities | (676,423) | |||||||||
Cash from financing activities | (301,859) | |||||||||
FCF | 1,312,219 | 1,279,915 | 631,957 | |||||||
Balance | ||||||||||
Cash | 3,661,619 | 3,580,687 | 3,552,948 | |||||||
Long term investments | 2 | 174,047 | 91,318 | |||||||
Excess cash | 3,060,526 | 3,181,026 | 3,117,021 | |||||||
Stockholders' equity | 6,310,546 | 5,994,545 | 5,283,354 | |||||||
Invested Capital | 4,654,899 | 3,982,995 | 3,209,065 | |||||||
ROIC | 34.03% | 41.47% | 41.69% | |||||||
ROCE | 21.05% | 22.58% | 21.38% | |||||||
EV | ||||||||||
Common stock shares outstanding | 1,163,269 | 1,169,353 | 1,169,324 | |||||||
Price | 16.26 5.65% | 15.39 -28.55% | 21.54 -38.61% | |||||||
Market cap | 18,914,755 5.10% | 17,996,337 -28.55% | 25,187,231 -39.09% | |||||||
EV | 16,172,687 | 15,084,747 | 22,403,426 | |||||||
EBITDA | 2,220,225 | 2,193,813 | 1,767,224 | |||||||
EV/EBITDA | 7.28 | 6.88 | 12.68 | |||||||
Interest | 28,582 | 34,230 | 59,230 | |||||||
Interest/NOPBT | 1.74% | 2.09% | 4.30% |